Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Deals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

Fineline Cube Jan 8, 2026
Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Policy / Regulatory

NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports

Fineline Cube Nov 29, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...

Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Company Deals

3D Medicines Set for IPO in Hong Kong, Aiming to Raise Up to USD 55 Million

Fineline Cube Nov 29, 2022

China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO)...

Company Policy / Regulatory

China’s Medical Product Trade Surplus Declines Amid COVID-19 Impact

Fineline Cube Nov 28, 2022

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Nuance Pharma Partners with DKSH to Launch Bentrio Nasal Spray in Hong Kong and Macau

Fineline Cube Nov 28, 2022

China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to...

Deals

Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement

Fineline Cube Nov 28, 2022

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...

Company Drug

Lyvgen Biopharma Initiates Phase II Study for LVGN7409 in Advanced NSCLC

Fineline Cube Nov 28, 2022

Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized...

Company Deals

ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round

Fineline Cube Nov 28, 2022

China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB...

Company

Ascentage Pharma Receives Drug Production License for Suzhou Plant

Fineline Cube Nov 28, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...

Company Drug

Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea

Fineline Cube Nov 28, 2022

China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...

Company

Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo

Fineline Cube Nov 28, 2022

The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine...

Company Deals

Huadong Medicine Partners with Dongyang Med for Equity Collaboration

Fineline Cube Nov 28, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang...

Company Drug

Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes

Fineline Cube Nov 28, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...

Drug

Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia

Fineline Cube Nov 25, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...

Company Medical Device

Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study

Fineline Cube Nov 25, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global...

Company Deals

Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub

Fineline Cube Nov 25, 2022

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...

Posts pagination

1 … 534 535 536 … 605

Recent updates

  • Hisun and ECNU Forge AI Drug Discovery Partnership
  • NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs
  • Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
  • Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
  • Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.